Related Experiment Video
Updated: Jun 2, 2026
11:31
Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
Published on: July 4, 2018
The cholinergic system in guttate psoriasis with special reference to mast cells
Experimental Dermatology
|April 28, 2011
Summary
Guttate psoriasis patients may benefit from anticholinergic treatment. This study reveals mast cells in psoriasis express acetylcholine receptors, suggesting a role for the cholinergic system in skin inflammation.
Area of Science:
- Dermatology
- Neuroimmunology
- Cell Biology
Background:
- Guttate psoriasis is an inflammatory skin condition.
- Mast cells are key players in the inflammatory response observed in guttate psoriasis.
- Previous observations suggest a potential benefit of anticholinergic treatments for guttate psoriasis patients.
Discussion:
- Mast cells in guttate psoriasis exhibit a distinct cholinergic profile, lacking acetylcholine synthesis enzymes but expressing acetylcholinesterase and various acetylcholine receptors (AChRs).
- Epidermal acetylcholine production and AChR expression shift to suprabasal layers in lesional skin.
- Acetylcholine, choline, and nicotine trigger mast cell degranulation in vitro, mediated by nicotinic AChRs, without inducing LTB-4 or TNF-alpha secretion.
Key Insights:
- Mast cells in guttate psoriasis are equipped with functional nicotinic acetylcholine receptors.
- The cholinergic system, particularly nicotinic pathways, directly influences mast cell degranulation in the context of psoriasis.
- Nicotinic acetylcholine receptor antagonists can inhibit acetylcholine-induced mast cell degranulation.
Outlook:
- Targeting nicotinic acetylcholine receptors on mast cells may offer a novel therapeutic strategy for guttate psoriasis.
- Further research into the precise mechanisms of cholinergic signaling in psoriasis pathogenesis is warranted.
- Investigating the role of epidermal acetylcholine in modulating mast cell activity could provide deeper insights.
Related Concept Videos
01:25Cholinergic Receptors: Muscarinic
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
01:30Parasympathetic Signaling
Parasympathetic signaling plays a crucial role in regulating various physiological processes. It involves the release of acetylcholine (ACh) by parasympathetic neurons, which can have localized and short-lived effects. The majority of ACh released is rapidly inactivated at the synapse by the enzyme acetylcholinesterase (AChE), which hydrolyzes Ach into choline and acetate. Additionally, the tissue cholinesterase deactivates any ACh diffusing into the surrounding tissues.
The effects of...
The effects of...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:27Esophageal Achalasia
Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide (VIP)...